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ABSTRACT
CAMERON E LEYERS. Elucidating the Effects of ERα: Isoform Expression and
Differential Receptor Localization in Immune Function. (Under the direction of MELISSA
A. CUNNINGHAM)
Estrogen can be anti- or pro-inflammatory depending on milieu and has a role in
increased incidence of lupus in reproductive age women versus men. Estrogen’s
pleiotropic effects are in part due to Estrogen receptorα (ERα) and its variants that localize
to cytoplasmic pools, nuclear regions and to the membrane. To understand the role of sex
hormone receptors in immune responses, we investigated the effects of altered ERα
isoform overexpression in dendritic and B cells. Toll like receptor 7 (TLR7) stimulated
endpoints, often dysregulated in lupus were also investigated. Genetically modified MOER
(membrane-only ERα) and NOER (nuclear-only ERα) mice were used to investigate the
effects of membrane versus nuclear ERα.
Transfection experiments were conducted using the Neon Electroporation system.
In vitro studies utilized transfected DC2.4 cells (a murine dendritic cell line) as well as a
human SLE EBV-transformed B cell line. Transfected cells were stimulated with TLR7
agonist for 1.5 hours and used either for vitality assays or RNA processed for Nanostring
analysis. Bone marrow harvested from ovariectomized NOER mice cultured with GM-CSF
and IL-4 for 7 days to generate BM-DCs, also treated for 1.5 hrs with TLR7 agonist and
stained to observe NFκB p65 translocation.
Preliminary results show that cells overexpressing ERα46 compared to ERα66
differentially express multiple genes critical in inflammation and immunity. Top genes
altered in DC2.4 include IL1α and IL1β. Interestingly, ERα 46:66 co-expression was similar
in DC2.4 while B cells resulted in significant downregulation in genes such as Nfatc3 and
Hif1a. Nanostring analysis has started to highlight altered pathways such as NFκB and
MAPK. WST-1 assays suggests that ERα66 is more proliferative. NOER BM-DC stains
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show little to no translocation of NFκB p65 to the nucleus before or after stimulation
suggesting membrane ERα is necessary.
Continued studies are needed to clarify the role of ERα isoform expression and
localization in immune cell function. Results between B cells and DCs highlight the ability
for ERα to act on different immune cells. These recent data share similarities in altered
genes previously seen in RNAseq of BM-DCs from ERα short mice supporting a
connection between ERα short and ERα46.

x

CHAPTER 1: INTRODUCTION AND BACKGROUND

Introduction
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease
characterized by loss of immune self-tolerance, autoantibody production and immune
dysregulation. Dysregulated immune cells such as overactive B and T cells and dendritic
cells that fail to properly clear apoptotic debris along with their inflammatory mediators
have been associated with SLE. These dysregulated immune cells and functions lead to
symptoms that at times will flare in severity while other times will wane or go into what’s
known as remission. For some, symptoms remain mild but for others SLE will lead to death
either through end organ damage or other serious complications (ex. infection). Ninety
percent of those affected are women, peaking during ages 15-44 when women are most
hormonally active. [8, 13, 46] In fact, being female is one of the strongest risk factors for
developing lupus. Even though lupus is one of the more recognized autoimmune diseases,
the pathogenesis of disease is still incompletely defined. Multiple lines of research have
indicated that lupus pathogenesis results from interactions among factors including
genetics and environment, as well as hormone levels and sex chromosomes, likely
impacting the sex bias in lupus and other autoimmune diseases. Other areas being
explored that likely effect the sex bias include X/Y translocations, differential X inactivation,
and epigenetics of the sex chromosomes themselves. [45, 63, 69] [42] Lupus incidence
in females declines to a 2:1 ratio vs. males when estrogen levels drop after menopause,
providing a strong epidemiologic indicator that estrogen plays a role in disease.
Determining the role estrogen plays in driving the sex bias seen in immunity and
autoimmunity will provide mechanistic insight into lupus as well as other autoimmune
diseases with a female predominance.
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Estrogen Receptor
Estrogen's signaling effects are mediated via estrogen receptors alpha and beta
(ER α/β) and have been shown to initiate pro- and anti-inflammatory actions through a
wide array of immune pathways. [24] Whether actions are pro-, or anti-inflammatory
depend on the conditions involved such as type of stimulus, concentration, location and
timing etc. [26] [4] ERs are low abundant in immune cells compared to expression levels
in reproductive tissue, making them difficult to study with traditional techniques such as
protein localization or immunohistochemistry. Even with low expression levels in immune
cells it has been clearly demonstrated that ERα is important to immune cell function as
well as development of immune-mediated diseases. [41] [14] A clear example is observed
through genetic deficiency of ERα in murine models of lupus where mice had significantly
decreased disease and prolonged survival, while ERβ deficiency had minimal to no effect
in murine lupus models. [62] Our lab continues its focus on ERα encoded by the human
ESR1 gene. The ESR1 sequence creates the full-length ER, ERα66, named according to
its molecular weight of 66kDa. It creates a protein composed of 595 amino acids divided
into six functionally distinct domains, A-F. The N terminal is made up an A and B domain
containing the transcriptional activation domain (AF-1). Activity of the AF-1 domain is
constitutive and can be moderated by the type of ligand, cell type and through a promoter
specific manner. [7] [65] [66] The C domain contains the DNA binding domain (DBD) and
is where the receptor recognizes and binds to specific sequences called estrogen
responsive elements (ERE). These and other downstream sequences allow direct
interaction with co-activators that can enhance transcription. [31] The D domain is a hinge
between the C and E domains and is involved in important receptor conformational
changes. This is also the location of the nuclear localization signal (NLS), which is required
for interactions with other transcription factors in the nucleus such as C-Jun or SP-1. The
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E domain or ligand-binding domain (LBD) which contains AF-2 functionality, is the binding
site for most cofactors. This domain is also critical for the binding of selective estrogen
receptor modulators (SERMs) which offer potential therapeutic benefits. [38] Without
ligand to bind, the E domain is involved in folding to form stable dimers. [64] [2] On the Cterminal is the F domain whose function potentially modulates recruitment and interactions
between various ligands.
ERα Isoforms
Further adding to estrogens pleiotropic actions is the variation in the presence and
ratio of receptor isoforms that can vary themselves based on timing, cell and tissue type,
among a multitude of other things. [56] [22] [40] [55] In addition to ERα66, the most
abundant form, truncated isoforms including ERα46 and ERα36 are formed through
splicing and alternative promoter usage. [19] [18]

Variants like ERα46 can also be

translated from normal ERα transcripts in vitro as a consequence of ‘leaky’ ribosomal
scanning allowing the ribosome to initiate transcription at a second start codon further in
the sequence which is also surrounded by a “Kozak” sequence further promoting
transcription. [33] [33] ERα46 is identical to ERα66 except for the truncation of the first
173 amino acids including the A/B domains removing AF-1 function completely. The lack
of AF-1 domain contributes to its weak transcriptional activity when stimulated with
estradiol in reproductive tissues. This variant may compete with ERα66 or may be
involved in non-genomic actions, more so than the full-length variant. [50][15] [18] ) The
DBD, LBD and AF-2 domains remain structurally intact in the shorter isoforms, which are
still able to bind coactivators and ligand/SERMS. Not only do these isoforms potentially
have their own independent functions but they also may interact to influence each other.
Overexpression of ERα46 antagonized the proliferative action of ERα66 in MCF-7 cells
partially through inhibiting ERα66 AF-1 activity. [51] [16] Although the actual role that ERα
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variants play in immune cells is unclear, studies in breast cancer biopsies have revealed
high concentrations of ERα46 in smaller tumors whereas an alternate variant, ERα36, has
been linked to increased tumor growth. [2] [51] The presence of either variant is linked to
disease prognosis and indicates that these isoforms have differential impacts in human
disease.
Modified ER Models
An ERα knockout model was created in the 1990s by the Korach lab by insert of a
neomycin (neo) resistance gene. The insert, placed approximately 270 bp downstream of
the ERα translation start site, leads to a frameshift that results in expression of a mutant
ERα protein rather than a complete knockout model. [37] Our lab now refers to this model
as ERα short since it was found to contain a N-terminal truncated ERα variant similar to
ERα46. It is considered a functional knockout in reproductive tissue due to its inability to
transactivate following E2 in classical signaling pathways, likely due to missing its
functional AF-1 domain. Backcrossing this model expressing an ERα mutant that is
structurally similar to ERα46 onto a lupus prone mouse, resulted in protection from
nephritis and significantly increased survival, despite similar serum autoantibody levels.
RNAseq performed on bone marrow-derived dendritic cells (BM-DCs) from these
lupus prone ERα short mice treated with Toll Like Receptor (TLR) 7 and 9 agonists
revealed over 2000 significantly differentially expressed genes. Inflammatory signaling
pathways including IL-6 and IFN were some of the most dysregulated pathways. Classic
complement system genes including C1qA, C1qC, and C1qB were also significantly
differentially expressed. [15] Deficiency of these complement proteins is strongly
associated with the development of human lupus. [12] TLR stimulation induced an even
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greater number of differentially expressed genes between WT and ERα short lupus
prone mice, supporting the potential importance of ERα46 in modulating TLR7-stimulated
signaling. These experiments indicate that ERα may modulate lupus disease expression
by impacting DC TLR signaling. An increase in ERα46 expression or action could shift E2
signaling to favor downregulation of inflammation and/or proliferation.
Using a true complete ER knockout model (ERα null) it was seen that full loss of
ERα resulted in increased levels of autoantibodies and no improved survival rates in mice
that had been ovariectomized (OVX) to control for aberrant hormone levels. The protective
phenotype was present with increased levels of testosterone and estrogen but not when
estrogen only was repleted (which led to worsened disease). Combined, these data
suggested that the protective phenotype in ERα null mice was not due to loss of ERα but
rather the increased testosterone, which has been seen in other lupus mouse models. [54]
Interestingly, a comparison of ERα Short and ERα-/- models showed that OVX’d lupus
prone mice with estrogen repletion expressing a truncated ERα were protected, and did
not require testosterone, but did require estrogen. ERα short mice repleted with estrogen
had normal testosterone levels and still had significantly increased survival as well as
decreased inflammatory B cells and DCs, supporting the hypothesis that the loss of AF-1
is protective and/or that ERα46, also missing its AF-1 domain may be protective as well.
[16] [15]
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Table. 1.1: Table with relevant structure schematics of ERα isoforms.
Outlined are the schematics with the domains for Wildtype, ERα Short,
ERαKO, NOER and MOER mice along with the major location each isoform
is expressed. To the right of each schematic is the identifier based on the
molecular weight. Only relevant isoforms have been included, isoforms such
as ERα36 are not shown.
AF-1, AF-2 = activation function domain 1, 2; LBD = ligand binding domain;
DBD = DNA binding domain; H =hinge region; C447 Palm = palmitoylation
site targeting ERα to membrane.
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Membrane versus Nuclear localization
ERα is found throughout most tissue types and is classically known as a nuclear
hormone transcription factor; immunohistochemistry methods have shown it to be
predominately located in the nucleus. ER typically binds to estradiol (E2) in the cytoplasm
before subsequently dimerizing and translocating to the nucleus where it binds to EREs
to impact transcription, either by inhibiting or promoting gene expression. (Figure 1.2) This
classical signaling mechanism does not account for other (likely non-genomic) effects that
are too rapid to be attributed to nuclear functions, including the rapid activation of multiple
kinase pathways such as NFKB, MTOR, and AKT [2] [9]. Differential localization of ERα
and its variants to cytoplasmic, nuclear and membrane regions of the cell allows E2 to
enact a variety of physiological functions including those in immune cells, likely allowing
for both pro- and anti-inflammatory actions. At this point in time membrane vs. nuclear
ERα function(s) in immune cells have not been elucidated. Definitive localization of ERα
variants has been hindered by the difficulty of immunocyto/histochemistry approaches for
identification of ERα variants outside of the nucleus. It is likely that not only technique, but
cell type and timing have a large impact on presence of ERα in different locations leading
to sometimes confounding results.[2, 14, 35]
Using MOER (Membrane Only ERα) [48] or NOER (Nuclear Only ERα) [49] mice,
a kind gift from collaborator Ellis Levin, membrane ERα actions and nuclear ERα actions
have begun to be separated to better define membrane and nuclear ERα-mediated
effects. Nuclear only ERα mice are created through a mutation that precludes
palmitoylation and therefore membrane trafficking, while membrane only ERα mice
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contain only the E domain which is sufficient for membrane signaling. NOER mice
present with abnormal vascular function, diminished formation of the mammary gland after
puberty, and are infertile due to abnormalities in the uterus lining and cystic ovaries. [49]
In contrast to NOER mice, MOER mice are designed with a nonfunctional DBD leaving
the LBD for membrane association. Female MOER mice showed atrophy in reproductive
organs, and rudimentary mammary gland development like those of complete ERKO mice.
With the creation of MOER mice it was clear to see loss of functioning nuclear ERα is
critical for normal organ development and that membrane ERα alone is not sufficient to
make up for the loss of nuclear receptors in reproductive organs. [48] Not only organ
development is affected but it has been shown in differentiated 3T3-L1 cells that
membrane ERα inhibits triglyceride content and that this is a nuclear ER-independent
mechanism. [47] This is exhibited in the MOER mice that visibly show more visceral fat in
their abdomen.
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Figure 1.1: Relevant ERα mechanisms. Highlighted in the above schematic
are genomic and non-genomic pathways of ERα. Nuclear or genomic
signaling occurs when estrogen binds to ERα and translocates to the nucleus.
This action induces transcriptional changes in estrogen responsive genes.
Membrane-initiated (non-genomic signaling, also termed MISS, membraneinitiated signaling by steroid) occurs when the membrane bound receptor
interacts with signaling kinase cascade(s) such as PI3K/MAPK to activate
transcription factors in the nucleus or initiate rapid effects. Variation and
differential localization of isoform expression in either membrane or nuclear
signaling may differentially impact immune responses. E2= Estradiol
TF=Transcription Factor
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TLR7 Activation
This study focuses on immune activation via Toll-like receptor signaling,
specifically TLR7, which is linked to both sex bias and development of lupus. TLR signaling
provides an alarm to initiate an immune response from both the adaptive and innate
immune system.

When dysregulated, TLRs have been linked to inflammation and

autoimmune disease development. Dendritic cells express TLRs and respond to TLR
ligands rapidly to initiate and bridge both innate and adaptive immune functions. When
dysregulated, DCs have been linked in both human and mouse studies to lupus secondary
to poor apoptotic debris clearance and increased Type I IFNs, among other irregularities.
The development and progression of SLE is in part related to the defective phenotypes
and homeostasis of DCs, and their altered interactions with B and T cells. [20] [3] [59] [59]
The impact of ERα46 on DC development and function as well as in vivo pathways
involved in membrane and nuclear ERα46-initiated events in response to TLR7 stimulation
in DCs has not been previously studied. To our knowledge, no studies in lupus or other
autoimmune diseases have utilized DCs or B cells overexpressing ERα variants to
investigate the impact of ERα46 or receptor localization (membrane vs. nuclear) on
disease. We suspect ERα46 modulates ERα66 activity, especially after TLR stimulation,
to impact the development and inflammatory actions of immune cells such as DCs. ERαshort’s ability to promote survival and blunt TLR stimulation in lupus prone mice is clear
but the mechanisms by which it acts are not.
The hypothesis that ERα46 and membrane localization will modulate immune
cells such as dendritic or B cells to be less inflammatory and more tolerant in response
to TLR activation was evaluated. Aim 1 tested the hypothesis that ERα46 impacts
dendritic cell development and signaling in response to TLR7 stimulation, while Aim 2
tested the hypothesis that different localization patterns (membrane vs. nuclear) of ERα
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impact immune cells as well as their response to TLR7 stimulation. These will be
discussed in Chapters 2 and 3 respectively.
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CHAPTER 2 - ERα ISOFORM ACTIONS IN DENDRITIC AND B CELL
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Introduction:
Our lab previously found that protected lupus mice expressing ERα Short had
altered development of DC subsets with a population of reduced activated DCs and
increased tolerogenic DCs (Figure 2.1) suggesting that ERα Short alters the population of
DCs that develop from BM. Plasmacytoid Dendritic Cells (pDCs) from these lupus prone
mice were reduced but also produced less IFNα, suggesting that pDCs are less active as
well. [15] Due to the structural similarities between ERα Short and endogenous variants,
it is of interest to see if ERα46 has the same effect on DCs and can potentially be targeted
to improve DC function.
Recent lupus studies revealed a defective DC phenotype that is marked by
decreased ability to induce tolerance and increased costimulatory expression and cytokine
release leading to a pro-inflammatory/activated phenotype. [30, 44] Similar to lupus
patients, DCs from lupus mice have an overactivated phenotype. [30] Since ERα Short
impacts DC development and function, further investigation of ERα variants in DC and
other immune cell biology may lead to insight into the pathogenesis of lupus. [32] [14]
The following experiments were designed to determine if ERα46, an endogenous
short variant, impacts DC or B cell function, two cell types involved in lupus pathogenesis.
Since TLR7/9 stimulation induced a large number of differentially expressed genes
between WT and ERα Short- expressing lupus prone mice (as demonstrated by RNAseq),
supporting the potential importance of ERα Short in modulating TLR signaling, TLR7
agonism was utilized as the main immune cell stimulant.
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Figure 2.1: Flt3L-cultured BM from lupus prone ERα Short mice
Cultured BM-DCs were stained for flow analysis. A reduced percent of cells
stained with MHCII+CD11c+, used as markers of CDCs, was seen in the
ERα Short group. There was an overall reduced cell count and reduced
percent of MHCII+CD11c+ cells but also an altered ratio of tolerogenic
(CD8a+CD11b-) vs. inflammatory (CD8a-CD11b+) DCs. ERαShort mice had
the lowest population of inflammatory DCs and the highest tolerogenic
population.
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Results:
Inflammation Panel in Dendritic cells.
To begin to understand the effects of overexpressing ERα66 and ERα46 and the
response to TLR7 stimulation, the Nanostring platform was utilized to study the expression
of genes associated with inflammation in 2 cell lines (DC and B cells) stimulated with
TLR7. RNA from both DC2.4 dendritic cells and SLE EBV-transformed B cells
overexpressing ERα46, ERα66 or a ratio of 1:1 ERα46 and ERα66 (referred to as ERα
Combo for simplicity) was collected +/- stimulation. Transfection efficiency ranged from
20-40%, which is robust for the transfection of immune cells.
ERα46 vs ERα66
Unstimulated DC2.4 cells transfected with ERα46 compared with DCs transfected
with ERα66 revealed downregulated expression of inflammatory genes in the interleukin
family and other chemoattractants such as IL1α, IL1β, Il6, Ccl7, Ccl2. This implies that
DCs expressing ERα66 are activated and have specific changes to inflammatory
pathways at baseline that are different than in cells expressing ERα46. Interestingly,
genes upregulated in ERα46-expressing cells include those in a different, but still critically
important inflammatory pathway: the Type I IFN signaling pathway: eg. Oas2, Oas1a, Irf7,
Ifi2712a, Ifi44, and Ifit3. IFNα has been strongly implicated in the pathogenesis of lupus in
humans and lupus prone mice. [28] It was found that pDC-derived Type I IFN upregulates
TLR7 expression in B cells, increasing TLR7 sensitivity in B cells. [6] [25] This suggests
that ERα46 does have inflammatory actions but through different mechanisms. ERα66transfected cells that were stimulated with a TLR7 agonist also had higher expression of
inflammatory chemokines similar to control samples, and also had lower expression of
some of the same Type I IFN signaling components. Unsurprisingly, these differences
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were exaggerated in the setting of stimulation. Compared to DCs overexpressing ERα66,
DCs overexpressing ERα46 had lower expression of Nfκb1 and Myd88 when TLR7treated IL1β and IL1α had the largest increased fold change between the two groups and
this difference in expression was amplified when stimulated with TLR7 agonist. Overall,
similar gene alterations were seen between DCs overexpressing ERα46 compared to
ERα66 both at resting and when stimulated, suggesting fundamental changes in DC
function even without an inflamed milieu.
ERα Combo vs ERα66
ERα66 and ERα Combo results were much more similar than thos between ERα66
and ERα46, as shown in Figure 2.2. ERα Combo shows no differentially expressed
downregulated genes compared to DC overexpressing ERα66 suggesting that the
combination of ERα46 and ERα66 are working in cooperation. Upregulated genes include
HIF1a, a gene that can bind with ERα to activate PI3K to increase expression of VEGF in
breast cancer cells and are increased in ER positive tumors. [29] Il6, as well as IFN genes
Ifit7, Ifit3 are also more highly expressed in DCs overexpressing ERα Combo. While TLR7stimulated ERα66-expressing cells had increased expression in Il1α, Il1β and Ccl5 when
compared to ERα Combo, the combo expressed more C1qa, C1qb, and Ptgs2. This data
supports the possibility that ERα46 and ERα66 may cooperate/coordinate to enact
different functions and interact with different genes than ERα46 or ERα66 can separately.
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Figure 2.2: MDS Plot of DC2.4 Gene Expression of ERα46, Erα66, and
ERαCombo.
This plot shows the closeness of the relationships between Erα46, ERα66
and ERα Combo. This clearly demonstrates the differences between Erα46
and Erα66 and Erα Combo. The relationships show that Erα66 and ERα
Combo share closer expression to their treated sample compared to Erα46
to its treated sample.
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ERα46 CTL vs LOX
TLR7-stimulated DC2.4 overexpressing ERα46 exhibited the largest fold increase
from its baseline state in Rps6ka5 (Rlpk) expression. Stimulated RLPK plays a role in
RELa (NFκB p65) transcriptional activity by associating with NR3C1 to inhibit RELa
transcription and repression of inflammatory gene expression. [67] [5] Other genes with
increases in expression after TLR7 activation are Hif1a and Pla2g4a. TLR7 stimulation
resulted in lower expression of genes such as Csf3, Oasl1, Irf7 and C1qb compared to
unstimulated. OASL1 has been shown to inhibit IRF7 and mice deficient in OASL1 had
increased levels of IFNα making them more resistant to certain viral infections. [34] Fold
changes between stimulated and unstimulated cells suggest that multiple inflammatory
actions are inhibited in cells overexpressing ERα46, suggesting that, similar to ERα Short,
ERα46 blunts TLR-stimulated signaling pathways.
ERα66 CTL vs LOX
TLR7-stimulated DC2.4 cells overexpressing ERα66 revealed the biggest increase
in Il1α expression. Other inflammatory genes like Il6 and Cxcl3 were also upregulated
after TLR7 activation. Genes such as C1qa, C1qb and Ifi27l2a had lower gene expression
after TLR7 stimulation compared to untreated, possibly suggesting a more activated
complement system at rest.
ERα Combo CTL vs LOX
Rock2 was the only gene determined to be differentially expression inTLR7stimulated DCs expressing both ERα46 and ERα66 (ERα Combo). ROCK2 is a
downstream protein indicating Rho Kinase activation and plays a large role in balancing
pro- and anti-inflammatory actions through a variety of cellular processes. [43] [70]
Through Rho kinase activation of NFKB, ROCK2 promotes the increase of inflammatory

19

TNF-α, IL-1β, IL-6. This suggests that ERα Combo is either in an activated state prior to
stimulation or has diminished response to TLR7 stimulation.
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Table2.1: Genes that are differentially expressed after TLR7 Stimulation
(A/B) Comparisons made between stimulated groups vs. control groups to see
how TLR7 treatment for 1.5 hours impacted gene expression. Genes
highlighted in red or blue are genes that are differentially expressed in the
same way. Note ERα Combo is not listed because it only has one differentially
expressed gene, Rock2.
A.

B.

ERα66 TLR7 Stimulated

ERα46 TLR7 Stimulated

INCREASED
EXPRESSION

DECREASED
EXPRESSION

Il1α

c1qA

ATF2
Il6

c1qB
Ifi27l2a

Hif1a

Trem2

Ifit1

Tyrobp

Tgfbr1

Ddit3

c1qb

Nr3c1

Irf7

MapK8

Oasl1

Ifit2

Jun

TLR7

Mapkapk2

TLR7

Cebpb

Pla2g4a

Oas1a

Map3k7

Tcf4

Ccl7

Map2k4

Mef2c_Mm

Tubb5

Hmgb1

Cltc

INCREASED
EXPRESSION

DECREASED
EXPRESSION

Rps6ka5

Csf3

Hif1a

Oas1a

Pla2g4a

Gapdh

Nr3c1

Shc1

Atf2

Tgfb1

Cd86

Irf7

Tgfbr1

Mef2c_Mm

Map3k1

Tlr4

Ptk2

Il1rap

Il1rn

Nfatc3
Il1β
Mapk8
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ERα46 vs ERα Combo and ERα66
Since alterations between ERα Combo and ERα66 cells are much smaller
between both groups, they were placed together as a control to compare against ERα46
using Rosalind Analysis Software. Eliminating genes that have a fold change that is less
than 1.5 and a p value > 0.05, 37 of the 250 panel genes were altered. As above with
Nanostring Analysis, ERα46-expressing cells had lower expression of genes like Il1α,
Ccl2, Ccl7, Hif1. DCs overexpressing ERα46 have higher expression of Type I IFN-related
genes like Irf5, Oasl1,and Oas1a. Genes that are downregulated in ERα Combo and
ERα66 have similar expression levels while many of the genes that have increased
expression to ERα46 are more variable between ERα Combo and ERα66. (Figure 2.3)
This suggests that specific pathways are being altered depending on which ERα isoform
is expressed. Heat maps show upregulated and downregulated genes in comparison to
ERα46 (Figure 2.3). According to Rosalind pathway analysis pathways of ERα46, ERα
Combo and ERα66 involved include the p38 MAPK signaling pathway, IL-1 signaling
pathway and TNF-alpha/NF-kb signaling pathway, in agreement with our Nanostring
analysis.
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A.

B.

Figure 2.3: 6 Differentially Expressed Genes Organized by Increase or
Decrease
A. Heat map showing 6 genes that are more highly expressed in ERα46
cells. ERα66 and ERα-Combo are similar.
B. This heat map shows 6 genes most downregulated in cells expressing
ERα46 when compared to ERα66 and ERα Combo. A difference
between ERα66 and ERα Combo can also be observed demonstrating
that, perhaps surprisingly ERα Combo has the highest gene expression
of these 6.
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Inflammation Panel in SLE EBV Treated B cells
The same methods were used to carry out NanoString analysis with SLE EBVtransformed B cells. RNA from ERα66, ERα46, and ERα Combo +/- TLR7 stimulation was
collected for analysis. Currently comparisons to untreated B cells overexpressing ERα46
cannot be made due to a quality-control issue However, comparisons can be made using
treated and untreated ERα Combo and ERα66. Of note, this cell line was derived from
human SLE patients (diseased) and are EBV-transformed, which likely impacts baseline
gene expression. Unstimulated cells transfected with ERα66expressed >100-fold more
Hif1a, Mef2c_Mm, Tcf4 and Stat3, with Hif1a being the most highly differentially expressed
at a >200 fold increase. After TLR7 stimulation, Hif1a was still >100-fold increased in
ERα66-expressing cells (compared with ERα Combo). Stat3 also remained differentially
expressed, but moreso after TLR7 stimulation. Nfatc3, Gnas were additional genes
identified that were over 100-fold different. When TLR7-treated, ERα46-expressing cells
had a 260-fold change increase in the gene Mef2c_Mm and 92-fold change increase in
Ccl5 compared with treated ERα66-expressing cells. Genes such as Tcf4 and Tnfaip3
were also upregulated. Tnfaip3 inhibits TNF-induced NF-Κβ effects and therefore proinflammatory effects helping to maintain immune homeostasis. [10] [61] Variants that lead
to reduced expression of Tnfaip3 cause a predisposition to autoimmune diseases such as
lupus. [68] On the other hand high expression of Tnfaip3 has been seen to negatively
correlate with ERα expression and is significantly increased in tumors with more
aggressive prognosis. [23] The increased expression of these genes in ERα46 compared
to ERα66 suggests that ERα46 is participating in cell activation and differentiation in B
cells. Lower expression of Mapk3, Nfatc3 and Jun was seen in treated ERα46 compared
to ERα66 groups. The Rosalind Analysis platform was also used to compare ERα66 to
ERα Combo, using a filter to remove genes with fold changes <1.5 or >-1.5, or a p value
>0.05. Figure 2.4 shows 6 genes that are
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differentially expressed as well as after TLR7 activation highlighting the different actions
in ERα66 and ERα Combo. When ERα was overexpressed in 293T cells NFATC3 was
repressed but the nuclear accumulation was not suggesting that the reduction in
expression was not from the loss of localization to the nucleus. Interestingly the expression
of ERα Combo had lower expression of NFATC3 than just the expression of ERα66
potentially indicating synergistic activity between ERα46 and ERα66.
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Figure 2.4: ERα66 CTL/ERα66 LOX vs. ERα Combo/ERα Combo LOX in B
cells
Heat map of 6 genes that are differentially expressed and their response when
stimulated with TLR7.
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Proliferation of DC2.4
To determine the impact of ERα46 overexpression on proliferation and vitality of
cells we utilized a WST-1 assay. Approximately 300,000 ERα-transfected cells were
placed in 10 wells and allowed to incubate for 48 hours before 1.5-hour treatment with a
TLR7 agonist, loxoribine. Evaluation at 48 hours showed that the wells were no longer
equal. Although efficiency of transfection was high, the vitality of the cells had been
affected (Figure 2.5A).

Below is a representative WST-1 assay (n=2 experiments)

measured at one hour. Increased absorbance was seen in cells overexpressing ERα66,
suggesting increased metabolism of WST and thus an increased proliferation compared
to a no shock (NS) transfection control. Cells overexpressing ERα46 had absorbance
values similar to that of the control, suggesting no significant changes in cell proliferation.
(Figure 2.5B)
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A.

B.

Figure 2.5: WST-1 Assay Transfection and Absorbance
A. Picture on the left shows the no shock control, the middle is transfected
with ERα46 and furthest right shows ERα66 transfected cells. The
population is visibly different between NS control and cells transfected
with ERα66 or ERα46.
B. Values from WST-1 assay shows the changes in absorbance. Even
with large population differences ERα66 have a higher absorbance.
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Discussion
It was hypothesized that DCs overexpressing ERα46 would be less proliferative
and mature, while ERα66 overexpression would increase proliferation and activation. In
conjunction with a less activated state, DCs overexpressing ERα46 were predicted to be
less active metabolically.
For all transfections, efficiency ranged from 20-40% between all plasmids but
vitality varied greatly between different transfection experiments. Differences between
cell counts, transfection efficiency and the plasmids themselves create a certain amount
of variability between samples.
The WST-1 assay revealed differences in cells transfected with each of the ERα
variants, which was highlighted in the Nanostring analysis. Although the WST-1 assay
suggested increased proliferation in ERα66-expressing cells, we cannot make definitive
conclusions given the variability seen in the assays. Although each well was seeded with
the same number of cells, we cannot differentiate possible cell death from electroporation
and/or plasmid toxicity effects that might confound results. Cells transfected with ERα66
had increased absorbance but also had fewer cells than the no shock control. Even with
confounding variables, the assay does suggest ERα impacts vital pathways such as
survival, proliferation, or metabolism. Sorting cells using fluorescent overexpression is the
next step to continue understanding the effects of ERα46 and ERα66 at the same
efficiency and cell counts. A population of sorted cells would also be beneficial to seeing
smaller fold changes in the Nanostring analysis that may have been diluted out. Future
comparisons will utilize cells overexpressing empty vector and vectors of the same
molecular weight to eliminate potential variables not currently accounted for. Staining of
known proliferation and maturation markers such as MHCII, CCR7, CD80, CD86 (in
addition to DC-SIGN and Ki-97) will be beneficial and likely more accurate in determining

29

and untangling effects on survival, maturation, metabolism, and proliferation.

There is not a single pro- or anti-inflammatory action or pathway that is easily
implicated when overexpressing ERα46 or ERα66 or the combination. Perhaps, this is to
be expected as estrogen itself is not straightforward impacting many different cell types
and functions. Il1α and Il1β exhibited the largest fold changes and are potent proinflammatory cytokines involved in acute and chronic inflammation in SLE. [11] [53] Lower
expressed genes suggest DCs overexpressing ERα46 have lower NFκB expression.
These recent data share similarities in altered genes that were previously seen in our
RNAseq using cells from ERα short-expressing mice, supporting a connection between
ERα Short and ERα46. Genes that were most altered in the RNAseq data including C1qa
were also highlighted in the ERα46 and ERα66 Nanostring studies.
DC overexpressing ERα66 data has increased C1q at unstimulated Special
attention should be given to the decrease in expression of C1qa as the loss of C1qa leads
to severe lupus disease expression and is heavily implicated as a high-risk gene. C1q has
many functions and could be acting in multiple processes such as the downregulation of
autoreactive B cells or could potentially be marking a point in maturation as the DCs lose
their ability to phagocytose (and the ability to produce C1q is downregulated). [58]
While not as many altered genes as in DCs., the comparisons made from gene
expression changes in B cells, lead to larger fold changes between these genes. ERα46
differential expression in genes like Mef2c_Mm and CCL5 suggest that upon activation
pathways, messages for proliferation and activation of nearby cells are sent. Further
comparisons will be made with B cells overexpressing ERα46.
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Currently, conclusions that can be drawn have to be made on the assumption that
it is not just the loss of overexpression of ERα66 that causes the effects but actually the
overexpression of ERα46. Even with confounding variables related to transfection and
overexpression, it is clear that ERα66 and ERα46 have differential effects on DC and B
cell function. Not only is there an impact but ERα isoform expression appear to be
impacting different mechanisms in each cell type. This study has also highlighted ERα’s
ability to modulate TLR7-initiatedsignaling pathways, altering the inflammatory reaction.
Many genes that are highlighted have been implicated in SLE patients such as Type I IFN
and C1q, again suggesting that these actions potentially contribute to the pathogenesis of
lupus. Evaluation of expression level of each isoform protein has yet to be evaluated and
will be confirmed to ensure equivalent transfection of each plasmid and that ratios are as
expected.
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CHAPTER 3: LOCATION, LOCATION, LOCATION
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Introduction:
In addition to Erα46 and ERα66 variants, differential localization of ERα to
cytoplasmic, nuclear and membrane regions of the cell allows estrogen to enact diverse
physiological functions, possibly including those in immune cells (ex. allowing for either
pro- or anti-inflammatory actions depending on milieu). The classical model of ER
requires ER to bind to ERE but it was soon realized that these actions were much faster
than DNA transcription could be. It was observed that within 15 seconds of IV E2 in
ovx’d mice the levels of CAMP were doubled (58) meaning this was the result of the
activation of quick signaling kinases and not binding through an ERE. As with all things
Estrogen, mechanisms likely differ between cell types, settings, timing and many other
variables that estrogen is affected by.
Membrane ER has been observed co-localized to caveolae where kinases such
as Src, SHc and ERKs are also enriched. ERα has been shown to activate the Src/Shc/
ERK pathway which leads to a decrease in cell death in multiple cell types. This
happens through the E domain and only when at the membrane as when ER was
targeted to the nucleus the effect was lost. (59) The importance of ERα localization to
the membrane in immune cells like dendritic cells are currently unknown. Defining
different genomic and non-genomic actions that ER is responsible for will illuminate
various mechanisms and pathways potentially creating a new drug target.
Using the MOER and NOER mice we were able to investigate membrane and
nuclear actions separately. Preliminary results showed that nuclear ERα leads to
reduced cellularity as well as a reduction in cultured BM-DCs in contrast to trends toward
increased percentage of B cells (CD19+) in the bone marrow. On the other hand,
MOER mice had increased classical dendritic cells (MHCII+/CD11c+/CD11b+). These
results are similar to those of the ERα short mice and suggest that the protective nature
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of ERα short (and possibly ERα46) are acting through membrane ERα-initiated events.
It also suggests that membrane ERα-initiated events are important to the development of
certain innate immune cell subsets and are required for robust expansion of DCs (Figure
3.1) Defining mechanisms by which estrogen exerts its potent immune effects is critical
to understanding how ERα impacts lupus disease expression

Figure 3.1 BM Immunophenotyping
Immunophenotyping revealed an overall lower population of cells in BM but
trended towards a higher population of B cells. CDC’s also were significantly
lower than the population in NOER mice.
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Results:
MOER and NOER IL-6 Response
Spleen immunophenotyping in preliminary studies revealed few significant
differences between MOER and NOER mice, but spleen cells from NOER and MOER
mice treated for 18 hours with a TLR7 to reveal long-term effects had a significant
reduction in IL-6 response. While not significant MOER mice trend to have higher IL-6
concentration.

Figure 3.2- IL-6 Response
IL-6 levels in supernatant demonstrate the significant reduction in
inflammatory cytokine IL-6 in NOERs. Mice that only have membrane ER
induced the same or more IL-6 when stimulated suggesting that membrane
actions play a big role in IL-6 production.
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MOER and NOER Hormone
It is known that hormone levels of testosterone and estradiol cause large shifts in
pro and anti-inflammatory immune functions. A well-known example of this is exhibited in
reduction seen in disease activity in pregnant women with rheumatoid arthritis while
pregnancy tends to cause flares in patients with SLE. (60) (61) To evaluate circulating
hormone levels blood was collected from WT, MOER and NOER mice. While trending
towards elevated NOER mice do not show significantly different levels from the MOER
mice. On the other hand, MOER mice have significantly elevated testosterone and
estradiol levels.

Figure 3.3- Circulating Hormone Levels
Elisa assay shows that MOER mice have significantly increased estradiol and
testosterone levels. This is likely impacting development and activation of
immune cells and processes.

36

P65 translocation in NOER BMDC’s
To distinguish if NF-ΚB translocation was affected by membrane or nuclear ERα,
BMDC’s isolated from 3 ovx’d NOER mice were cultured for 7 days in GM-CSF and IL-4
to create . BMDCs were exposed to 1.5-hour lox treatment to capture short term effects.
After 1.5-hour BMDC’s were stained in wells with DAPI nuclear staining and staining for
NFΚB p65 which is primarily located in the cytoplasm of unstimulated DC’s. Control and
treated samples showed little difference between the groups. This suggest that p65 is
unable to translocate to the nucleus after stimulation with TLR7 agonist, possibly because
the absence of membrane ERα prohibits transportation across the membrane.
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A.

B.

C.

Figure 3.4- Stained NOER BM DCs
A. Untreated Stack: p65 is clearly seen outside the nucleus shown in
green
B. Treated Stack: Possibly some p65 but a large majority is located
outside of the nucleus meaning it is not translocating past the
membrane
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Discussion:
Even when highly expressed Erα can be hard to visualize so a lower expressed
isoform like ERα46 is even more difficult to visualize in a cell type with lower expression
like an immune cell. Repeated attempts of visualization in both overexpressed cell lines
and MOER/NOER cell lines proved to be fruitless. Ongoing efforts are looking for different
methods to visualize localization of ER. use. Using the NOER and MOER mice allows our
lab to do localization work without visualization. Supernatant collected from NOER/ MOER
splenocytes revealed a decrease in IL-6 production from the NOER mice. These results
are similar to the significant decrease of IL-6 seen in RNAseq of BMDC’s from lupus prone
Erα-Short mice suggesting a connection between the short ERα variant and membrane
localization that that may result in a lupus protective effect. All though splenocytes used
for IL-6 analysis come from unmanipulated mice, NOER mice have less altered hormone
levels than those of the MOER mice. This experiment should be conducted again with
OVX’d mice, but the NOER response is not expected to change. It would also be beneficial
to capture this effect at different time points to observe it this differences in short term and
long term effects.
When investigating MOER and NOER mice BM and splenocytes it was expected
that there would be drastic changes within the two populations just taking into
consideration the known importance of nuclear ER. Instead, populations were fairly similar
with no significant changes in population or responses. This heterogeneity is possibly
caused by the aberrant hormone levels of both estradiol and testosterone especially in the
MOER mice. High estradiol levels in MOER mice seem contradictory at first since there is
no nuclear estrogen receptor to bind with ERE but is caused by the loss of estrogen’s
negative feedback regulation of the hypothalamic-pituitary axis. (38) NOER mice also
have increased levels of estradiol and indicates a hormonal role for membrane Erα action,
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all though to a lesser degree than nuclear. Hormone trends in MOER and NOER mice
correlate with previous data seen in the creation of the MOER and NOER mice. (62)
Currently our lab is conducting ovariectomy surgery at age and pelleted with E2 to replace
a normal concentration of hormones. At age 12-14 mice are treated with R848 or acetone
and will be sacrificed for flow cytometry on BM and splenocytes. Results can then be
directly compared to previous results to eliminate any trends caused by altered hormone
levels.
Without comparison pictures from MOER and WT mice it is difficult to make a
conclusion regarding the changes of p65 localization. MOER and WT samples are needed
to ensure that p65 localization is maintained and only lost when membrane ERα is
nonexistent. A sample size of 8 mouse bone marrow samples per group and an average
of 2 mice per litter to provide 80% power is ongoing. Data shows that un manipulated
NOER mice had a largely reduced IL-6 response after TLR7 stimulation. If MOER mice
maintain their p65 localization, and with the indication of NOER mice not showing p65
translocation to the nucleus when stimulated with agonist suggests that membrane Erα is
critical in activating NFKB pathways and therefore the expression of inflammatory
cytokines such as IL-6. While visualization is ongoing continuing to define mechanisms by
which estrogen exerts its potent immune effects is critical to understanding how ERα
impacts lupus disease expression.
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS

41

Many of ERα interactions and mechanisms remain shrouded in darkness,
especially those that act in immune cells. Obviously continued studies are needed to
clarify the role of ERα isoform expression and localization in immune cell function. By
beginning to untangle mechanisms of Estrogen Receptor through its localization and
isoforms separately we have begun working out how E2 is impacting signaling pathways
and their products shining light into the unknown.
Nanostring analysis has been extremely useful in highlighting altered pathways
such as NFκB, MAPK and IL1. Results from transfected DC’s and B cells have confirmed
a role of ERα in immune cells while at rest and that this action is impacted when stimulated
with TLR7 agonist. Not only does ERα have actions in immune cells, but actions also
appear to be cell type specific as seen with the difference in genes between DC’s and B
cells fold changes. The expression of Erα46 impacts and interactions will be determined
with further added to Nano string comparison analysis.

Comparisons between ERα

overexpression should be compared to a GFP only sample to create a standard
comparison of transfection.
The loss of translocation of p65 to the nucleus in NOER mice suggests that
membrane ERα is crucial to NFκB activation. NFKB when activated is pro-inflammatory
suggesting that nuclear ER may also play a role in inhibiting inflammation.

The

mechanism that is involved here remains unclear. It’s known that ER can inhibit NFKB
expression, NFKB can inhibit ER function, and a multitude of crosstalk between the two
factors occurs.
It’s possible that both the loss of membrane Erα and nuclear Erα will cause a loss
of p65 translocation to the nucleus as they might be working in unison. It is most likely that
a multitude of pathways are altered. It has been seen that inhibiting any one of the three
Akt, p38, and JNK will inhibit NF-ΚB. (63) Due to the loss of membrane ERα, it’s been
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shown that NOER mice have loss of AKT phosphorylation which could also explain the
loss of p65 translocation Studies regarding localization will continue to be worked through
to further understand these mechanisms. More studies are needed to clarify the roles of
ERα localization in modulating immune cell development and function. Continued work
from MOER and NOER mice will reveal mechanistic functions of nuclear and membrane
era. Attempts to visualize ER will be continued, as new methods and antibodies are
developed.

Figure 5.1: Complexity of ER impacts on signaling pathways
This figure demonstrates various possible outcomes that may be
impacted by ERα. Outcome 1 leads to the transcription of NFKB while
outcome 2 shows ER binding to NFKB DNA preventing translation of
NFKB. Outcome 3 demonstrates how ER might interact to increase
Type I INFs compared to outcome 4. * ER can also prevent the
translocation of NFKB by preventing ubiquitination. **It’s possible that
ER could interact with IRF7 to inhibit type I INF’s.
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This study would be positively impacted by the implementation of a stable cell line
This stable cell line would eliminate the need for any cell sorting or unnecessary handling
which can be extremely beneficial due to the delicate nature of immune cells. If no stable
cell line transfected cells need to be sorted to create a population of equal number and
efficiency. Since ERα isoforms may exist in different levels, and potentially vary between
individuals, the impact of different ratios of ERα46 to ERα66 should continue to be
evaluated to better understand interactions as well as functional consequences of altered
variant levels. These studies will lead to insights on how ERα-Short provides protection
from lupus renal disease in females, and thus insight into the sex bias in lupus. Ratios will
help to analyze interactions between Erα46 and ERα66 as well.
Estrogen has many and variable effects on all body systems, including
reproductive, cardiovascular and immune systems making this a very complex but
important issue.

ERα variants and cellular localization allows for the complexity of

estrogen signaling and effects as well as contributes to the uncertainty of ERα
mechanisms. Some of this complexity is outlined in figure 4.1, outlining the many different
ways ER may affect signaling pathways. Expanding our knowledge of these mechanisms
is beneficial to our understanding of how sex hormones impact lupus disease expression
as well as to the autoimmunity field in general. This study focused on two predominant
ERα variants in humans: ERα66 and ERα46 along with the impacts of localization.
Findings from this study have started defining central functions of ERα in a primary DC
line, a transformed B cell line and provide a mechanistic basis for ERα modulation of
TLR7-stimulated immune cells.

Results from this study have started to separate

mechanistic capabilities of ERα46, potentially revealing possible therapeutic targets for
intervention that may delay lupus disease onset and/or progression. Future studies can
further investigate differences between AF-1 function or only AF-2 function. Defining
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mechanisms in which estrogen can enact it’s protective as well as detrimental effects will
be critical for the design of safe and targeted treatments.
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CHAPTER 5: METHODS AND MATERIALS
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Data and Statistical Analysis
Nanostring Analysis
Differential Expression was determined through Nanostring N solver. The DE
Call (Differential Expression call) is an error model to assist in determining confidence of
ratios when no replicates exist. The DE Call is a mapping of raw count values to an
estimated level of 95% of technical variability. Only genes that passed the DE call are
referenced above.

Rosalind Analysis
Data was analyzed by ROSALIND® (https://rosalind.bio/), with a HyperScale
architecture developed by ROSALIND, Inc. (San Diego, CA). Read Distribution
percentages, violin plots, identity heatmaps, and sample MDS plots were generated as
part of the QC step. Normalization, fold changes and p-values were calculated using
criteria provided by Nanostring. ROSALIND® follows the nCounter® Advanced Analysis
protocol of dividing counts within a lane by the geometric mean of the normalizer probes
from the same lane. Housekeeping probes to be used for normalization are selected
based on the geNorm algorithm as implemented in the NormqPCR R library [52].
Abundance of various cell populations is calculated on ROSALIND using the Nanostring
Cell Type Profiling Module. ROSALIND performs a filtering of Cell Type Profiling results
to include results that have scores with a p-Value greater than or equal to 0.05. Fold
changes and pValues are calculated using the fast method as described in
the nCounter® Advanced Analysis 2.0 User Manual. P-value adjustment is performed
using the Benjamini-Hochberg method of estimating false discovery rates (FDR).
Clustering of genes for the final heatmap of differentially expressed genes was done
using the PAM (Partitioning Around Medoids) method using the fpc R library [27] that
takes into consideration the direction and type of all signals on a pathway, the position,
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role and type of every gene, etc. Hypergeometric distribution was used to analyze the
enrichment of pathways, gene ontology, domain structure, and other ontologies. The
topGO R library [1] was used to determine local similarities and dependencies between
GO terms in order to perform Elim pruning correction. Several database sources were
referenced for enrichment analysis, including Interpro [39], NCBIM [21] SigDB [60] [36]
REACTOME [17] WikiPathways [57]Enrichment was calculated relative to a set of
background genes relevant for the experiment.
WST-1 Assay
An ordinary One way Anova and tukeys multiple comparisons test with a single
pooled variance using each value from 5 wells subtracting the blank.
IL-6 ELISA
An ordinary two way Anova and Tukeys multiple comparisons test, with individual
variances computed for each comparison.
Hormone ELISAs
An ordinary one way Anova and Tukeys multiple comparisons test, with a single
pooled variance was used was used to compare Estradiol and Testosterone ELISAs
Translocation of P65
3 OVXd mice BM was cultured to create 3 different stains. These stains were
visually compared. More mice needed for more statistical power.
Plasmids:
pCMV-GFP (RRID:Addgene_11153) ,a kind gift from Gray Evans, was cotransfected with ER plasmids. ER plasmids were created through using Thermofisher
Geneart. The synthetic gene Erα66 and Erα46 were assembled from synthetic
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oligonucleotides and/or PCR products. The fragment was inserted into pMARQ (AmpR)
and pMS (SpcR/StrR) respectively. The plasmid DNA was purified from transformed
bacteria and concentration determined by UV spectroscopy. The final construct was
verified by sequencing. The sequence identity within the insertion sites was 100%. 5 µg
of the plasmid preparation were vacuum dried for shipping. DNA was extracted using
Qiagen Midi Plasmid Kit (Qiagen Valencia, California, USA) according to manufacturer’s
protocol. Concentration measured through Nanodrop.
ERα66 Sequence
ATGACCATGACCCTCCACACCAAAGCATCTGGGATGGCCCTACTGCATCAGATCCA
AGGGAACGAGCTGGAGCCCCTGAACCGTCCGCAGCTCAAGATCCCCCTGGAGCG
GCCCCTGGGCGAGGTGTACCTGGACAGCAGCAAGCCCGCCGTGTACAACTACCCC
GAGGGCGCCGCCTACGAGTTCAACGCCGCGGCCGCCGCCAACGCGCAGGTCTAC
GGTCAGACCGGCCTCCCCTACGGCCCCGGGTCTGAGGCTGCGGCGTTCGGCTCC
AACGGCCTGGGGGGTTTCCCCCCACTCAACAGCGTGTCTCCGAGCCCGCTGATGC
TACTGCACCCGCCGCCGCAGCTGTCGCCTTTCCTGCAGCCCCACGGCCAGCAGGT
GCCCTACTACCTGGAGAACGAGCCCAGCGGCTACACGGTGCGCGAGGCCGGCCC
GCCGGCATTCTACAGGCCAAATTCAGATAATCGACGCCAGGGTGGCAGAGAAAGA
TTGGCCAGTACCAATGACAAGGGAAGTATGGCTATGGAATCTGCCAAGGAGACTCG
CTACTGTGCAGTGTGCAATGACTATGCTTCAGGCTACCATTATGGAGTCTGGTCCT
GTGAGGGCTGCAAGGCCTTCTTCAAGAGAAGTATTCAAGGACATAACGACTATATG
TGTCCAGCCACCAACCAGTGCACCATTGATAAAAACAGGAGGAAGAGCTGCCAGG
CCTGCCGGCTCCGTAAATGCTACGAAGTGGGAATGATGAAAGGTGGGATACGAAA
AGACCGAAGAGGAGGGAGAATGTTGAAACACAAGCGCCAGAGAGATGATGGGGAG
GGCAGGGGTGAAGTGGGGTCTGCTGGAGACATGAGAGCTGCCAACCTTTGGCCAA
GCCCGCTCATGATCAAACGCTCTAAGAAGAACAGCCTGGCCTTGTCCCTGACGGC
CGACCAGATGGTCAGTGCCTTGTTGGATGCTGAGCCCCCGATACTCTATTCCGAGT
ATGATCCTACCAGACCCTTCAGTGAAGCTTCGATGATGGGCTTACTGACCAACCTG
GCAGACAGGGAGCTGGTTCACATGATCAACTGGGCGAAGAGGGTGCCAGGCTTTG
TGGATTTGACCCTCCATGATCAGGTCCACCTTCTAGAATGTGCCTGGCTAGAGATC
CTGATGATTGGTCTCGTCTGGCGCTCCATGGAGCACCCAGGGAAGCTACTGTTTGC
TCCTAACTTGCTCTTGGACAGGAACCAGGGAAAATGTGTAGAGGGCATGGTGGAG
ATCTTCGACATGCTGCTGGCTACATCATCTCGGTTCCGCATGATGAATCTGCAGGG
AGAGGAGTTTGTGTGCCTCAAATCTATTATTTTGCTTAATTCTGGAGTGTACACATTT
CTGTCCAGCACCCTGAAGTCTCTGGAAGAGAAGGACCATATCCACCGAGTCCTGG
ACAAGATCACAGACACTTTGATCCACCTGATGGCCAAGGCAGGCCTGACCCTGCA
GCAGCAGCACCAGCGGCTGGCCCAGCTCCTCCTCATCCTCTCCCACATCAGGCAC
ATGAGTAACAAAGGCATGGAGCATCTGTACAGCATGAAGTGCAAGAACGTGGTGCC
CCTCTATGACCTGCTGCTGGAGATGCTGGACGCCCACCGCCTACATGCGCCCACT
AGCCGTGGAGGGGCATCCGTG
GAGGAGACGGACCAAAGCCACTTGGCCACTGCGGGCTCTACTTCATCGCATTCCTT
GCAAAAGTATTACATCACGGGGGAGGCAGAGGGTTTCCCTGCCACGGTCTGA
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ERα46: Sequence
*GAAGTATGGCTATGGAATCTGCCAAGGAGACTCGCTACTGTGCAGTGTGCAATGA
CTATGCTTCAGGCTACCATTATGGAGTCTGGTCCTGTGAGGGCTGCAAGGCCTTCT
TCAAGAGAAGTATTCAAGGACATAACGACTATATGTGTCCAGCCACCAACCAGTGC
ACCATTGATAAAAACAGGAGGAAGAGCTGCCAGGCCTGCCGGCTCCGTAAATGCT
ACGAAGTGGGAATGATGAAAGGTGGGATACGAAAAGACCGAAGAGGAGGGAGAAT
GTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTGGGGTC
TGCTGGAGACATGAGAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACGCT
CTAAGAAGAACAGCCTGGCCTTGTCCCTGACGGCCGACCAGATGGTCAGTGCCTT
GTTGGATGCTGAGCCCCCGATACTCTATTCCGAGTATGATCCTACCAGACCCTTCA
GTGAAGCTTCGATGATGGGCTTACTGACCAACCTGGCAGACAGGGAGCTGGTTCA
CATGATCAACTGGGCGAAGAGGGTGCCAGGCTTTGTGGATTTGACCCTCCATGATC
AGGTCCACCTTCTAGAATGTGCCTGGCTAGAGATCCTGATGATTGGTCTCGTCTGG
CGCTCCATGGAGCACCCAGGGAAGCTACTGTTTGCTCCTAACTTGCTCTTGGACAG
GAACCAGGGAAAATGTGTAGAGGGCATGGTGGAGATCTTCGACATGCTGCTGGCT
ACATCATCTCGGTTCCGCATGATGAATCTGCAGGGAGAGGAGTTTGTGTGCCTCAA
ATCTATTATTTTGCTTAATTCTGGAGTGTACACATTTCTGTCCAGCACCCTGAAGTCT
CTGGAAGAGAAGGACCATATCCACCGAGTCCTGGACAAGATCACAGACACTTTGAT
CCACCTGATGGCCAAGGCAGGCCTGACCCTGCAGCAGCAGCACCAGCGGCTGGC
CCAGCTCCTCCTCATCCTCTCCCACATCAGGCACATGAGTAACAAAGGCATGGAGC
ATCTGTACAGCATGAAGTGCAAGAACGTGGTGCCCCTCTATGACCTGCTGCTGGAG
ATGCTGGACGCCCACCGCCTACATGCGCCCACTAGCCGTGGAGGGGCATCCGTG
GAGGAGACGGACCAAAGCCACTTGGCCACTGCGGGCTCTACTTCATCGCATTCCTT
GCAAAAGTATTACATCACGGGGGAGGCAGAGGGTTTCCCTGCCACGGTCTGA
*Kozak sequence left before start codon. (24)
Cell Systems
DC2.4 Dendritic Cells (Mouse Dendritic Cell)
DC2.4 are a kind gift from C. Vasu. They are immortalized murine dendritic cells
created by transducing bone marrow isolates of C57BL/6 mice with retrovirus vectors
expressing murine granulocyte-macrophage CSF (GM-CSF) and the myc and raf
oncogenes. DC2.4 were grown in 10% Fetal Bovine Serum (Atlanta Biologicals, GA,
USA), 1% penicillin/streptomycin, 1% L-glutamine, and 0.5% ampicillin (Corning, NY,
USA) Cells were maintained at 5% CO2, 37 °C, 100% humidity.
SLE EBV Transformed B Cells
EBV-transformed cell lines were originally generated from systemic lupus
erythematosus (SLE) patients and controls as a part of the Lupus Family Registry and
Repository. SLE EBV B cells were grown in 10% Fetal Bovine Serum (Atlanta
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Biologicals, GA, USA), 1% penicillin/streptomycin, 1% L-glutamine, and 0.5% ampicillin
(Corning, NY, USA) Cells were maintained at 5% CO2, 37 °C, 100% humidity.

Neon Transfection
DC2.4 and SLE EBV cells were harvested at 70-80% confluency. A total of 3 ×
106 DC2.4 or SLE EBV B cells were spun to form pellet. Media is decanted and cells are
resuspended in PBS and then pelleted. PBS is decanted. Cells are resuspended in
105ul of Buffer R. Electroporation was conducted with a Neon Transfection System
(MPK5000) (Invitrogen) under the following conditions:
DC2.4: voltage (1550 V), width (10 ms), pulses (three)
SLE EBV B cells: voltage (1350 V), width (30 ms), pulses (one).
Both cell types utilized the 100-μl tip. Cells were transfected with 5.0 μg of needed
plasmid and 5.0ug of CMV-GFP. Combination groups are made of 2.5 ug ERα46 and
2.5 ug ERα66. Immediately after electroporation, cells were plated in a 6-well plate in
2ml of warmed complete RPMI containing 15% Fetal Bovine Serum (Atlanta Biologicals,
GA, USA), and 1% L-glutamine (Corning, NY, USA). After 1 hour DC2.4 media is
removed and replaced with complete RPMI 10% Fetal Bovine Serum (Atlanta
Biologicals, GA, USA), 1% penicilalin/streptomycin, 1% L-glutamine, and 0.5% ampicillin
(Corning, NY, USA). At 24 hours SLE EBV cells can be spun at 1500rpm for 5 minutes
and media can be replaced with complete RPMI 10% Fetal Bovine Serum (Atlanta
Biologicals, GA, USA), 1% penicilalin/streptomycin, 1% L-glutamine, and 0.5% ampicillin
(Corning, NY, USA). Efficiency was evaluated through image captures of microscope
evaluation of GFP+ to the GFP- cells at 24 and 48 hours using the 3 separate photo per
well. Counts were conducted manually through ImageJ software and calculations made
by GFP+ divided by the total cells in the field x 100 and then averaged per 3 wells.
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WST-1 Assay
A total of 3 × 106 DC2.4 cells were transfected and placed into 1 ml of complete
RPMI containing 15% Fetal Bovine Serum (Atlanta Biologicals, GA, USA), and 1% Lglutamine (Corning, NY, USA). 110 ul of mixture is placed into 10 wells of a 96 well
plate. Media is replaced with complete media after 1 hour and left to incubate overnight
at 5% CO2, 37 °C, 100% humidity. 24 hour and 48 hour efficiency was observed. At 48
hours, 5 of the 10 wells for each group were treated with 100um/ml loxorbine for 1.5
hours. At 1.5 hours cell proliferation was assessed by WST-1 (ab155902; abcam) assay
according to the manufacturer’s protocol.

RNA extraction
48 hours post transfection media is removed from cells. Cells are washed with
ice cold PBS and an appropriate amount of 4°C TRIzol (Invitrogen) is added. (DC2.4
work was done directly in plate, while SLE EBV B cells were collected and pelleted
through centrifuge) Samples were rocked for 30 minutes and was ready for downstream
processing. Chloroform is added to TRIzol in a 1:5 ratio. Shake for 1 minute, rest at RT
for 3 minutes. Centrifuge and carefully remove aqueous layer. Add equal parts 70%
ethanol and place solution into Qiagen RNAeasy kit column Follow manufacture protocol
utilizing the DNAase step. Concentration determined by Nanodrop.

Mice
Mice were bred and housed at the Ralph H. Johnson VA animal facility
(Charleston, SC, USA). Animal protocols followed the principles outlined in the Guide for
the Care and Use of Laboratory Animals and approved by the Ralph H. Johnson CAMC
IACUC. Membrane-Only Estrogen Receptor (MOER) and Nuclear-Only Estrogen
Receptor (NOER) mouse strains were originally a kind gift from Dr. Eric Levin (Veterans
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Affairs Medical Center, Long Beach, CA, USA). Mice were maintained on a 12-hr.
light/dark cycle with access to food and water ad libitum. The phenotypic study consisted
of MOER, NOER, and wildtype (WT) female mice between the ages of 13-29 weeks
(n=59). The TLR7 treatment study consisted of female mice between the ages of 12-16
weeks (n=15). Littermates were used when possible.
Genotyping
MOER and NOER mice are based on the C57BL/6 mouse background. The
following primers pairs were utilized to confirm the MOER genotype: Primer 1 (5’TTGCCCGATAACAATAACAT-3’), Primer 2 (5’-ATTGTCTCTTTCTGACAC-3’), Primer 3
(5’-GGCATTACCACTTCTCCTGGGAGTCT-3’), and Primer 4 (5’TCGCTTTCCTGAAGACCTTTCATAT-3’). DNA was isolated from tail snips of 4 weekold mice using DirectPCR (Tail) Lysis Reagent and Proteinase K solution (Viagen, Los
Angeles, CA). DNA samples were incubated at 56°C overnight with a final digestion at
95°C for ten minutes. PCR conditions for the MOER mice are as follows: 94°C for 5
minutes, with 30 cycles of 94°C for 1 minute, 55°C for 1 minute, 72°C for 1 minute, and a
final cycle of 72°C for 5 minutes. Homozygous MOER mice have no PCR product for
primers 1/2 and a 255 bp band for primers 3/4. WT littermates have a 387 bp band from
primers 1/2 and an 815 bp band for primers 3/4.
The NOER genotype uses the following primers: Primer 1 (5ʼ- CTAAACAAAGC
TTCAGTGGCTCCTAG-3′), Primer 2 (5′-ACCTGCAGGGAGAAGAGTTTGTGTG-3′),
Primer 3 (5′-ACCTGCAGGGAGAAGAGTTTGTGGC-3′), and Primer 4 (5′CTCCTCTTCAGACCTGAAG TTCCTAT-3′). DNA was isolated as described above.
PCR conditions for NOER mice are: 94°C for 3 minutes, with 30 cycles of 94°C for 45
seconds, 64°C for 45 seconds, 72°C for 90 seconds, and a final cycle of 72°C for 5
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minutes. Homozygous NOER mice have a 400 bp band, while WT littermates have a
590 bp band.

Measurement ofSerum hormone levels
All mice used female aged 16-20 weeks. Testosterone ELISA analyzed 11 WT, 6
MOER, and 9 NOER. Estradiol ELISA analyzed 10 WT, 6 MOER, and 11 NOER. Blood
samples were collected by cardiac puncture, left to sit at room temperature and
centrifuged to remove serum. Serum was stored until assayed using Calbiotech estradiol
and testosterone ELISAs following manufactures protocol. (Calbiotech, ES380S)
Spleen and Bone Marrow Processing
Spleens were harvested and kept in cold, complete RPMI containing 10% Fetal
Bovine Serum (Atlanta Biologicals, GA, USA), 1% penicillin/streptomycin, 1% Lglutamine, and 0.5% ampicillin (Corning, NY, USA). Spleens were disassociated through
40 um strainers, depleted of red blood cells with red blood cell lysis buffer (144 mM
NH4Cl and 17 mM Tris, pH 7.6), and washed twice with cold RPMI. The single cell
suspension were kept on ice until processing. One subset of spleens (n=9) were cultured
for 18 hours with lox so that supernatant and cells could be collected for analysis.
Bone marrow was flushed from the tibia and femur of both hind limbs and processed
through 70 um strainers for a single cell suspension. Bone marrow cells were treated
with red blood cell lysis buffer and washed twice with cold RPMI. BMDC’s were cultured
from total BM using GM-CSF (100 ng/ml) and IL-4 (50ng/ml. After 7 days BMDCs are
scraped, spun and plated in a 6 well plate at a concentration of 1.0 x 106 cells/ml in
complete RPMI media for downstream use.
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IL-6 ELISA assays
Using 3 WT, 4 MOER and 5 NOER mice ages 12-18 splenocytes were cultured
at 1 x 106 cells/ml RPMI with either vehicle or loxoribine (TLR7 agonist; 200 uM/ml).
After 18 hrs, culture supernatants were harvested and IL-6 concentrations were
measured via ELISA per manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA) using
a microplate luminometer (Thermo Scientific Multiskan Ascent).
Staining
Three NOER mice that had been OVX’d, aged 12-to 13, were sacrificed for
spleen and BM processing. BMDC’s were cultured as stated for 7 days. Supernatant
was removed from wells, and wells washed with PBS. BD Perm/Wash™ buffer for 15
minutes. BD PERM/Wash buffer was removed, 250 µL of BD Perm/Wash™ buffer
containing rabbit anti-NF-κB p65 monoclonal antibody (1:1000; Cell Signaling
Technology, Danvers, MA, USA; Cat# 8242) Incubate on ice for 30 minutes in the dark.
Wash cells 2 times with 1× BD Perm/Wash™ buffer. 250 µL of BD Perm/Wash™ buffer
containing Goat Anti-Rabbit IgG H&L FITC-conjugated secondary antibodies (1:200; cat.
no. ab6717; Abcam) f. Incubate on ice for 30 minutes in the dark. Wash cells 2 times
with 1× BD Perm/Wash. Seal with 2-3 drops VECTASHIELD HardSet Antifade Mounting
Medium with DAPI.
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